Anzeige
Mehr »
Login
Montag, 31.03.2025 Börsentäglich über 12.000 News von 695 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A40UCN | ISIN: CA4576377002 | Ticker-Symbol: MWG
Frankfurt
31.03.25
09:31 Uhr
1,850 Euro
-0,570
-23,55 %
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
INMED PHARMACEUTICALS INC Chart 1 Jahr
5-Tage-Chart
INMED PHARMACEUTICALS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,8701,96015:47
1,8701,96015:44

Aktuelle News zur INMED PHARMACEUTICALS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
14.02.InMed Pharmaceuticals: Finanzbericht zeigt Umsatzrückgang und Verlust9
13.02.InMed Pharmaceuticals Inc. - 8-K, Current Report-
INMED PHARMACEUTICALS Aktie jetzt für 0€ handeln
13.02.InMed Pharmaceuticals GAAP EPS of -$3.64, revenue of $1.11M5
13.02.InMed Pharmaceuticals: InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update471Vancouver, British Columbia--(Newsfile Corp. - February 12, 2025) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of...
► Artikel lesen
12.02.InMed Pharmaceuticals Inc. - 10-Q, Quarterly Report-
03.02.InMed Pharmaceuticals Inc. - 8-K, Current Report1
03.02.InMed erzielt Fortschritte bei AMD-Behandlung mit vielversprechender IVT-Wirkstoffformulierung-
03.02.InMed Pharmaceuticals: InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration195INM-089 IVT formulation selected for continued developmentDemonstrated successful delivery at doses up to 10 times the projected therapeutic level, indicating a favorable pharmacokinetic profile and...
► Artikel lesen
22.01.InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds253Marks the first jurisdictional issuance of an international patent for a family of novel small molecule compoundsPatent covers novel analog compounds for therapeutic applications in pain, glaucoma...
► Artikel lesen
22.01.InMed Pharmaceuticals sichert sich internationales Patent9
22.01.InMed Pharmaceuticals secures international patent3
21.01.Why InMed Pharmaceuticals (INM) Stock Is Skyrocketing3
21.01.InMed Hails Alzheimer's Study, Stocks Shoot Higher-
21.01.InMed Pharmaceuticals Inc. - 8-K, Current Report-
21.01.InMed Pharmaceuticals: InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study267INM-901 significantly reduced pro-inflammatory cytokines associated with Alzheimer'sStatistically significant reduction in neurodegeneration marker, neurofilament light chain ('NfL')mRNA profile showed...
► Artikel lesen
30.12.24InMed Pharmaceuticals Inc. - S-1/A, General form for registration of securities3
23.12.24InMed Pharmaceuticals Inc. - S-1, General form for registration of securities4
20.12.24InMed Pharmaceuticals Inc. - S-8, Securities to be offered to employees in employee benefit plans3
19.12.24InMed Pharmaceuticals: InMed Announces Results of 2024 Annual General Meeting461Vancouver, British Columbia--(Newsfile Corp. - December 18, 2024) - InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of...
► Artikel lesen
18.12.24InMed Pharmaceuticals Inc. - 8-K, Current Report1
Seite:  Weiter >>
49 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1